NCT07728188
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 7 words
- Trial sites reduced: 66 → 7 locations
- Start date changed from estimate of Nov 30, 2026 to Oct 20, 2026
- Secondary endpoints: details revised at 6 of 21 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Safety Run-In: Number of Participants With Adverse Events (AE)s
Timeframe: Up to Approximately 75 Months
Randomized Portion: Complete Response (CR) or Better Rate Per Independent Review Committee (IRC) Assessment
Timeframe: Up to Approximately 75 Months
Randomized Portion: Progression-Free Survival (PFS) Per Independent Review Committee (IRC) Assessment
Timeframe: Up to Approximately 75 Months
Secondary (21)
Safety Run-In: Best Overall Response (BOR) of Per Investigator Assessment
Safety Run-In: Maximum Observed Concentration (Cmax) of Etentamig
Safety Run-In: Time to Cmax (Tmax) of Etentamig
Safety Run-In: Area under the Serum Concentration-Time Curve (AUC) of Etentamig
Safety Run-In: Immunogenicity of Etentamig
Show 16 moreShow less
Randomized Portion: Minimal Residual Disease Negative Complete Response (MRDnegCR) Per IRC Assessment
Randomized Portion: Overall Survival (OS)
Randomized Portion: Sustained Minimal Residual Disease (MRD) Negativity
Randomized Portion: Best Minimal Residual Disease Negative Complete Response (MRD Negative CR) Per IRC Assessment
Randomized Portion: BOR Per IRC Assessment
Randomized Portion: VGPR or Better Rate Per IRC Assessment
Randomized Portion: Time to Response (TTR) Per IRC Assessment
Randomized Portion: Duration of Response (DOR) Per IRC Assessment
Randomized Portion: Second Progression-Free Survival (PFS2)
Change From Baseline in EORTC QLQ-C30 Global Health Status/Quality of Life (QoL) Score
Randomized Portion: Event-Free Survival (EFS) Per IRC Assessment
Randomized Portion: Time to Next Treatment (TTNT)
Randomized Portion: Time to Symptomatic Disease Progression
Randomized Portion: Change From Baseline in Disease Symptoms as Measured by the Disease Symptoms Domain of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Myeloma Module (EORTC QLQ-MY20)
Randomized Portion: Change From Baseline in Physical Functioning as Measured by the Physical Functioning Domain of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Randomized Portion: Overall Bother Due to Treatment Side Effects as Assessed by the Functional Assessment of Cancer Therapy - General Population, Item 5 (FACT-G GP5)
Arms and interventions
Safety Run-In: Etentamig Plus PomalidomideExperimental
Participants will receive etentamig in combination with pomalidomide, as part of the approximately 75 month study duration.
Randomized Portion: Etentamig Plus PomalidomideExperimental
Participants will receive etentamig in combination with pomalidomide, as part of the approximately 75 month study duration.
Randomized Portion: Standard Available Therapy (SAT)Active comparator
Participants will receive Investigator's choice of SATs: DPd, DKd, or teclistamab monotherapy as part of the 75 month study duration.
Drugs: Etentamig, Pomalidomide, Daratumumab, Dexamethasone, Carfilzomib, Teclistamab
Sites
7 sites in 4 countries
Japan 4, Israel 1, Taiwan 1, United States 1